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Abstract 
To compare the long-term effectiveness of whole pancreas transplantation and pancreatic islet 
transplantation in controlling the metabolic disorders and preventing the kidney lesions of alloxan diabetes, 
metabolic and morphologic studies were performed in four groups of rats: (1) NC-116 nondiabetic controls; 
(2) DC-273 untreated alloxan-diabetic controls; (3) PDT -182 rats that received syngeneic 
pancreaticoduodenal transplants not long after induction of diabetes with alloxan; and (4) IT-92 rats that 
received an intraportal injection of at least 1500 and usually 2000 syngeneic pancreatic islets soon after 
induction of diabetes with alloxan. Each month for 24 months after diabetes was well established, body 
weight and plasma concentrations of glucose and insulin were measured, and five lesions were scored by 
light microscopy in 50 glomeruli and related tubules in each kidney by a "blind" protocol: glomerular 
basement membrane thickening, mesangial enlargement, Bowman's capsule thickening, Armanni-Ebstein 
lesions of the tubules, and tubular protein casts. There were progressive and highly significant increases in 
the incidence and severity of all five kidney lesions in the diabetic control rats compared with the 
nondiabetic control rats. No significant differences were found between the kidneys of Group PDT and 
those of Group NC, demonstrating that whole pancreas transplantation prevented all of the diabetic kidney 
lesions throughout the 2-year study period. In contrast, within 3-9 months after pancreatic islet 
transplantation and thereafter, the incidence and severity of the five diabetic kidney lesions were similar in 
Group IT and Group DC. Whole pancreas transplantation produced precise metabolic control of diabetes 
throughout the 24 months of study, whereas pancreatic islet transplantation did not accomplish complete 
metabolic control, particularly beyond the first several months after transplantation. The difference in the 
completeness of metabolic control achieved by the two types of transplants is the most likely explanation 
for their sharp difference in effectiveness in preventing diabetic nephropathy. 
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catecholamines, and growth honnone, but it has not 
accomplished long-term normoglycemia.64.6S A number 
of recent studies have reponed progression of nephropa~ 
thy21-23 and retinopathYtl 4-12 and failure to improve 
neuropathyJ2 during insulin pump therapy, perhaps be-
cause metabolic control has not been sufficiently precise 
to reverse the diabetic lesions. 
The development and progression of diabetic ne-
phropathy have not been prevented by conventional 
treatment with insulin injections and diet.a-Io Nephrop-
athy often develops in normal kidneys transplanted into 
diabetic recipients for end-stage renal failure, despite 
coneened efforts at metabolic control with conventional 
therapy.6l>-69 Our previous findings that whole pancreas 
transplantation is capable of preventing GBMT and 
ME. and our current demonstration that pancreatico-
duodenal transplants are effective in preventing all rena} 
lesions of experimental DM, suggest that whole pan-
creas transplantation may be indicated in patients with 
end-stage diabeti<: nephropathy who require kidney 
transplantation and, therefore, must be given immuno-
suppression therapy for life. The outlook for the useful-
ness of pancreatic islet transplantation appears less 
promising. 
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Discussion 
DR. JOHN S. NAJARIAN (Minneapolis, Minnesota): I want to con-
gratulate the author on a very nice presentation of studies that we have 
followed with interest over the yeaB. 
J am, at one point, however, concerned about the conclusions that 
Dr. Orloff has reached. Therefore, J would like to state a few facts and 
ask a couple of questions. 
In 1974, in the journal Diabetes. we showed that syngeneic islets, 
when transplanted to rats, can prevent, as well as revene, the lesions of 
experimental diabetes in the kidney. This finding was reported in a 
syngeneic rat system in which the recipient rat was made diabetic with 
streptozotocin. a diff'erent form of bela cell poison than alloxan. This 
reversal was complete for diabetic lesions, which occurred within 3 
months of streptozotocin treatment. However, if we waited 6-9 
months, we could not reverse the lesions, which now became colla-
gen-filled and irreversible. In its early and proliferative stages, however. 
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the mesangial matrix material. which is the sine qua non of this lesion, 
could be reversed. 
In 1975, armed with this information, we progressed to treating 20 
patients who were Type I diabetics with allogeneic islets. We trans-
plan1ed them with what we believed were enough islets, and yet, in 
each instance, we were only able to reduce their insulin requirements 
but never cure a single patient (insulin independence). 
We temporarily gave up on this technique and went back into the 
clinical arena to perform segmental organ transplantation of the pan-
creas, as we had done initially in 1966 with whole organ pancreatico-
duodenal transplants. Since 1978, we have performed 185 segmental 
or whole organ pancreas transplants. 
At the same time we were pllZZled with what happened to the trans-
planted islets in the previous clinical series. Was it a fact that we did not 
techoical1y transplant viable islets, or was the laclc of success due to 
immunologic rejection? 
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To dctennine which phenomenon was responsible for this failure, 
we investigated a series of patients with chronic small duct pancreatitis. 
We removed their pancreases. isolated the islets, and gave them back 
their own (autologous) islets, so there could be DO immunologic con-
sequences. 
Under those circumstances, even though the number of islets was 
limited, half of these patients did not require further insulin, and 
currently, we have seven patients on isolated autogenous islets trans-
planted to the liver who do not require insulin and have excellent 
metabolic control. Our technique, therefore, was good; therefore, there 
must be immunologic problems that need to be solved to make islet 
allotransplantation swxessful. 
Dr. Sutherland and 1 then went on and did 185 pancreatic orpn 
transplants, wbo5e results we presented to this Association, and clini-
cally 60% of these transplants have worked very well. With pancreas 
tranSPlants, we have seen partial reversal of triopathy; the renal lesions, 
the retinal lesions, and the neurologic lesions. 
It is tempting to hope that the islets would work because, in fact, it 
would involve less surgery. In addition. you have enough islets so that 
you could treat more than one patient with the islets obtained from a 
single cadaveric donor. 
It bas been shown by various groups that you can transplant islets 
and achieve a completely normal glucose tolerance curve. This has 
been shown by David Sharp in St. Louis, Gus NossaI's group in Aus-
tralia, Conrad Federle in Germany, and John Paul Squiftlet in Brus-
sels. All of these investigators bave shown that with islets they can get 
nonnal glus:ose tolerance curves and can prevent the lesions that Dr. 
0rI0If observes with animals that receive pancreatic transplants. 
Thus, what has happened in the Orlolf experiment with islet trans-
plantation? We have found that when you put islets into the liver you 
lose about half of them. Therefore. we increased the number of islets 
transplanted sufficiently enough to get equivalent numbers of islets to 
those that we transplanted with whole orpn pancreas transplants. 
When we did that, there was no dilference between the results of 
pancreatic organ transplants and islet transplants. 
My question to Dr. Orlolf is: how did you measure the amount of 
islets or insulin content that you had in the liver? In addition, even the 
sliahtest bit of species dilference with islets would show the kind of 
erosion that he reported with the loss of islets with time. What SJ)CCi!:s 
did you use and what combinations? 
DR. KEITH REtiMTsMA (New York, New York): The question posed 
by Dr. Orloff is of central importance, and in his studies. islet trans-
plants do not work well. However. other investigators have found that 
islet transplants can, in the long run, produce normal metabolism and 
reversal of the vascular diabetic changes, as measured by renal function 
and morphology. 
The important question here is why, under the circumstances of this 
study, islet transplants do not function well. I would aaree with Dr. 
Orlolf that the most likely explanation for the vascular changes is the 
incomplete reversal of the metabolic state. But why? The pattern of 
failure suggests an inhospitable environment for the transplanted islets. 
Perhaps Dr. Orlolf could comment on the liver pathology, as alloxan 
produces periportal fibrosis, and this miaht interfere with islet func-
tion. 
These studies confinn that whole pancreas grafting is elfecti ve. and it 
results in byperinsulinemia. The eventual role of islet transplants, how-
ever, remains unanswered. 
DR. ROBERT J. CORRY (Iowa City, Iowa): I compliment Dr. Orlolf 
on an excellent paper reprding an important issue; that is whether or 
not successful pancreatic transplantation can prevent or stabilize the 
devastating secondary complications of Type I diabetes. In his study, 
rats who received islets did not achieve nonna! glucose control, sug-
gesting either that an insufficient supply of islets was administered or 
something happened to them in the first few months, such that normal 
glucose control could not be achieved. On the other hand, whole orpn 
pancreatic transplantation resulted in normal glucose metabolism and 
prevented complications. 
With regard to whole organ grafting we have reasons to be optimistic 
as a result of evidence emerging from a few U.S. and European pan-
creas transplant programs. In Stockholm. Carl Groth bas shown pre-
vention of the mesangiaI thickening in the glomeruli in patients who 
recei~ combined kidney aod pancreas grafts compared with another 
group ofpa1ients transplanted at the same time, namely diabetic recip-
ients whc) received kidneys only. AU patients who received ~neys and 
were followed after 3 years had microscopic changes of diabetes in the 
glomerulus, whereas none of the patients who received combined kid-
neys and pancreases bad any degree of mesanaiaI thickeniJIs. 
In addition, Walter Land in Munich has shown some evidence of 
reversal ofneuropathy as well as vascuIopatby. Donald Dafoe in Micb-
ipn has presented some interesting data showing that blood lipids are 
significantly lowered in patients who have received suocessful pancreas 
pafts. 
I would like to show a few slides indicating that wbole organ trans-
plantation of the pancreas does not necessarily preclude successful 
liver donation. This illustration shows the blood supply ofbotb orpns 
dissected. Essentially the gastroduodenal artery is ligated and the 
splenic artery is divided a few millimeters from its origin on the hepatic 
artery. The superior mesenteric artery is divided near the pancreas. 
The portal vein is divided IS it exits the pancreas. In this Way the blood 
supply for the donated liver will be normal, namely the aortic patch 
aod entire portal vein go with the liver. Extension grafts are placed on 
the pancreas under ice by taking a segment of donor iliac artery with 
both branches. The internal iliac artery is ~en joined to the superior 
mesenteric artery and the mernal iliac artery is joined to the splenic 
artery. Donor iliac vein is then used to extend the portal vein. These 
extension grafts are placed under iced solution so the ischemic time is 
not extended very much. 
DR. THoMAS E. STAllZL (Pittsburgh, Pennsylvania): This is a grand 
organization that we belong to and the prestige of the organization is so 
IfCltt that a paper presented here is apt to be construed as the last word. 
If we really ~ this paper on absolutely face value. this could be the 
death koeO of islet ceD transplantation. It is in that context that I want 
to make a few comments and this is where I am inclined to be in 
agreement with Dr. Najarian. 
Solid pancreas transplantation in principle as practiced successfully 
by Or. Orlolf and by others at Minnesota and elsewhere, is different 
than almost anything else we do. Ifwe transplant the kidney. there is 
no carrier tissue that comes along with the graft. It is a simple, 
straightforward intellectual exercise. If there is any carrier function 
that comes with the kidney, it might be the production of erythropoi&-
tin. The bean is a simple pump. and with the liver, practically every 
cell does something that is essential for the survival and health of the 
recipient. In the case of the pancreas we are transplanting an organ in 
whi~h if we transplant 100 g, almost all of that is tissue, which, first of 
all, IS not needed, and second, is a nuisance. That extra tissue a<:COunts 
for almost all the morbidity and mortality of whole organ pancreas 
transplantation, which is consi~bleK 
What are the options? One of the options is the procedure that fared 
so poorly in Dr. Orloff's comparison. I do not doubt for a moment his 
conclusions, but I must say that I still have hopes for islet cell trans-
plantation.1 hope that this paper, as fine IS it is, will not cause funding 
to be precluded for islet ceO research or elforts to be stopped by some of 
those groups that are still making those efforts such as Scharp in St. 
Louis, Lalferty and Wei! from Colorado, Mintz and Miller from 
Miami. and possibly others including Sutherland of Minnesota and 
Barker et aI. from Pennsylvania. 
Other options have to be carefully explored because of the deficien-
cies not only of whole orpn transplantation, but also of islet cell 
transplantation. One possibility might weD be gene splicing, in which 
cells are endowed with the ability to produce insulin. Anything that 
could move us in that direction would be valuable and certainly would 
be worth pursuing. 
The annals ofbistory, as my friend, Mark Ravitch. has reminded me 
often, are replete with missed opportunities. I could recount many but 
these would reveal my age. We do not have to go much farther back 
than last month's New England Journal 0/ Medici1U! in which there was 
a report from Mexico about succ;essful transplantation of adrenal tissue 
into the brain for the treatment of neuropsychiatric disorders. This was 
a procedure that bad been thoroughly discredited in previous Scandi-. 
ADa. Suq. • SepIeaaI)er 1911 334 ORLOFf' AND orHERS (§avian trials, but that now holds great promise instea4.1 hOJ)Cthat.;1 pa1ientswho have receivcdislet pausplants. (3) oeprdinagoha:Ds~te­transplantation or some analogue or derivative of that procedure is 0; J. meqt that many have s!Jowo comP;lete!y al~ OlTs ~ollowmg islet 
actually dead . transplantation, the facts are that if ODO ClI8IDUIC!II the literature aw-
. fWly, one wiD be hard-pressed to lind /ong-lmn, dellrty doc:umeDtcd 
DR. MARSHALL J. ORLOFF (Closing discussion): I am honored to normalization of the OTT. For exampl~ ReDOld's croup and ~Ds 
have this work discussed by some of the giants in this field, aQd there is ~p ~th fo~pd that the OTT ~~ ~~ numerous 
Jio doubt that they are the Jiants. Keith Reemtsma was working 00 studies. Including those from Dr. ~aqanan s own InstitutiOn E~~ 
pan~ transplantation wheo I wasjust a boy, and he reminded me of aI., Vialettes et ~KF haveK~ fail~ of plasma pucose and f~ 
~hat before he got up to discuss my paper. He !Iu made enormous ~ to lIonnalize ~ tlMtially lIl;1d tn ~ Iqna tenD. (4) !ohn~K 
contributions to this field. As to Jobo k~K wheneVer I present a Is it poIIlble that our islets were bcjng~? We used hiably ta~ 
paper:,lie always gets up and says: "It is a very mce piece ofwork, but Lewis fats. We have shown that these rats accept traDJplaJJts of skin, 
we did that back in 1970." And he is sometimes right. ltis Cllperimen- whole ~ liver, intestine, stomach. spleen, and heart without 
tal aRel clinical work and thal of his group, o.Vid Sutherland and the deveiORing clinical or bistoIosic evidence of rejection. Tbcfc was no 
others, has ~ mQnumcntal in the lietd ofpancreas transplantation. I histologic: evideoce whatsoever of immU1lOlOBic tejection of our islet 
gucssvnuwouldbayleiocall~Minnesotasrouptheleadiaa~ transplants. (5) AIWIy, Dr. k~ ~ how we ~ the 
transplantation croup in the world. Of course, 1 canllO.t even begin to volume ofislets transplanted. We counted the number of islets ~ 
describe what Tom Stanl bas done for evcrytbi.lI8 in transpJantjltion. It !lCQpically in an aliquOt of the islet SUSP,ODSion. We traaspIantcd ap-
is awesome. I bate to·think about it because I feci ~ infcriof after proximately 2000 isIcts, wbicll is men than ~ Dumber US!'d by the 
thinkingaJlout all the tIli¥ that he has done. Rob CoRy is a relative vast majority of ~ersK For example, in intraporta1 transplants, 
newcomer, the ne,v kid on the block. but the ~ts that they ~ Kipnis, Lacy et aI. used 350-1000 islets, BatIter et aI. used 400-SOO 
baving in Iowa with cliniqll transpJanWion of the PIlIlcreall are ex- islets, and Fcdcmn et aI. used 500-800. There is no q~ that our 
trcmely promising and they haye developed very rapidly. They cer- transplants were successlW, since they prod\lCCd normal pIaaQIa pu-
tainly have my respect. ., COIle and insulin levels for the first !leVetal months. Measurement of 
The main issue I believe, and it is a critical issue, is what degree of iAsulin OIJtpUt from the liVer is not a iood way of quaatitatilll the 
metabolic control is required to prevel\t md/or reverse ~ lesions of adequacy of the transplant, unless l'1:JI!!8ted measurem!mts over a lona 
diabetes, not just in the short term, but in the long term. Our Cllperi- periOd are made, and no one has done that. 
mental ~ta susBest, and in fact the clinical data iBcl~ng the data on Keith Reemtsma raised the passii!!lity that alloxan mi&bt cause peri,. 
insulin pump therapy suaest, that the control must be very ~!rld porta1 fibrosis that interferes with the viability of the isIcts. t~ have 
must be of long duration. Brief period,s of control for a ft;W months do studied several thousand rats with alloxan diabete$ and have never 
not really mean a lot. It has to be very precise and prololJ8ClCi. seen IUlY evidence of periportal fibrosis or bClJlltic chanies. Moreover, 
As far as we can tell, at 1east to this point, the most precise metabolic our islct tntDSpla!1ts were very viable for the first scveraI months. How-
control comes from transplrptting the whole pancreas. It is the only ever, .. others such as Barker et aI. have ~ in strcptozotocin 
form of endocrine pancreas replacement therapy that bas produced diabetes, th~ is a progressive lQSS of islets after initial metabolic con-
complete and prolonged metabolic control. trol, J believe because they do not bring their own supply of blood 
Reprding the comments bf Jobn ~arianI I bave the foUowing vessels and bavea very teBuousexistence. As time goes by, theisletiare 
response: (I) The 1974 report of his croup in TIu! JOW'fIIli qf &:peri- easily lost, perhaps .. a resuh of even ~ent reductioqs in hepatic 
mental Medicine. in which kidneys from 11 diabetic rats were trans- blood low and oxygen supply. 
planted ipto normal rats, did not show statistically significant reversal Tom StarzlIIIIde an inspirational sta~ment about continued fund-
of mesangial matrix thickening. Furthermore, this was a very short- ing for research in islet transplantation. I do not believe tliere is any-
tenn, nOD9uantitative study in which the kidneys were ~faoted thing to fear. Having worked in the field of porta1 byperteDlion for 
after only 6 months of diabetes and then were stpdied only 2 months many years, I bave often observed that notbing ctiesexcept the patients. 
later. [ do not believe any conclusions from this study, positive or Although I have considerable doubt about the ultimaIC SllClce8S of 
negative, an: possible. (2) As to his six patients who have recei~ islet transplantation, then: is no question that continuing research is 
autoJosous islets, the problem with all of theae case reports is that the ~ted along all avenues that could conceivably help the millions of 
patients have not had long-term, weU-estabiished diabetes before islet patients who suifer from diabetes. Moreover, islet ~ts bave 
tral)Splantation, and there is always the question of wl!ether the pa- provided and wiD continue to provide important information about 
tients would have had diabetes without the autologous islet traDSP.lan- many ~ of diabete$ and its treatment. An understandi.na of islet 
tahO!!. The hard facts 8J!: that there is !lot a single case of successful, physiology, islet immunolOl)',1UId prevention ofislet rejection are but 
prolonged relief of diabetes mellitus antong the more than 100 diabetic a few of the potential and actual benefits of islct transplant resean:h. 
